CD274 and non-small cell lung carcinoma: The efficacy of combination therapy with PD-1/PD-L1 antibody added to chemotherapy had clinically significant improvements in PFS and OS in patients with non-squamous (NS)-NSCLC compared with chemotherapy alone, irrespective of PD-L1 expression levels, and even better outcomes in patients with high PD-L1 expression by subset analyses.7–11 Therefore, PD-1/PD-L1 antibody improves survival outcomes when administered as monotherapy or combination therapy with chemotherapy, which is PD-L1 expression level-dependent.